Donors after circulatory death heart trial

Yasuhiro Shudo; Rhodalene Benjamin-Addy; Tiffany K. Koyano; William Hiesinger; John W. Macarthur; Y. Joseph Woo

doi:10.2217/fca-2020-0070

Donors after circulatory death heart trial

Yasuhiro Shudo, Rhodalene Benjamin-Addy, Tiffany K. Koyano, William Hiesinger, John W. Macarthur, Y. Joseph Woo

Research output: Contribution to journal › Review article › peer-review

33 Scopus citations

Abstract

Orthotopic heart transplantation is the gold standard treatment for end-stage heart failure. However, the persistent shortage of available donor organs has resulted in an ever-increasing waitlist and longer waiting periods for transplantation. On the contrary, increasing the number of heart transplants by preserving extended criteria donors and donation after circulatory death hearts with the Organ Care System™ (OCS) Heart System has the potential to provide the gold standard, life-saving treatment to patients with end-stage heart failure. The objective of the Donation After Circulatory Death Heart Trial is to evaluate the effectiveness of the OCS Heart System to preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation, which can potentially provide patients with end-stage heart failure with the life-saving treatment. Clinical Trial Registration: NCT03831048 (ClinicalTrials.gov.

Original language	English
Pages (from-to)	11-17
Number of pages	7
Journal	Future Cardiology
Volume	17
Issue number	1
DOIs	https://doi.org/10.2217/fca-2020-0070
State	Published - Jan 2021
Externally published	Yes

Keywords

donation after circulatory death
ex situ heart perfusion
heart transplantation

Access to Document

10.2217/fca-2020-0070

Cite this

@article{645b8b527b03466d9fb02282e0b84125,

title = "Donors after circulatory death heart trial",

abstract = "Orthotopic heart transplantation is the gold standard treatment for end-stage heart failure. However, the persistent shortage of available donor organs has resulted in an ever-increasing waitlist and longer waiting periods for transplantation. On the contrary, increasing the number of heart transplants by preserving extended criteria donors and donation after circulatory death hearts with the Organ Care System{\texttrademark} (OCS) Heart System has the potential to provide the gold standard, life-saving treatment to patients with end-stage heart failure. The objective of the Donation After Circulatory Death Heart Trial is to evaluate the effectiveness of the OCS Heart System to preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation, which can potentially provide patients with end-stage heart failure with the life-saving treatment. Clinical Trial Registration: NCT03831048 (ClinicalTrials.gov.",

keywords = "donation after circulatory death, ex situ heart perfusion, heart transplantation",

author = "Yasuhiro Shudo and Rhodalene Benjamin-Addy and Koyano, {Tiffany K.} and William Hiesinger and Macarthur, {John W.} and Woo, {Y. Joseph}",

note = "Publisher Copyright: {\textcopyright} 2020 ",

year = "2021",

month = jan,

doi = "10.2217/fca-2020-0070",

language = "English",

volume = "17",

pages = "11--17",

journal = "Future Cardiology",

issn = "1479-6678",

publisher = "Future Medicine Ltd.",

number = "1",

}

TY - JOUR

T1 - Donors after circulatory death heart trial

AU - Shudo, Yasuhiro

AU - Benjamin-Addy, Rhodalene

AU - Koyano, Tiffany K.

AU - Hiesinger, William

AU - Macarthur, John W.

AU - Woo, Y. Joseph

PY - 2021/1

Y1 - 2021/1

N2 - Orthotopic heart transplantation is the gold standard treatment for end-stage heart failure. However, the persistent shortage of available donor organs has resulted in an ever-increasing waitlist and longer waiting periods for transplantation. On the contrary, increasing the number of heart transplants by preserving extended criteria donors and donation after circulatory death hearts with the Organ Care System™ (OCS) Heart System has the potential to provide the gold standard, life-saving treatment to patients with end-stage heart failure. The objective of the Donation After Circulatory Death Heart Trial is to evaluate the effectiveness of the OCS Heart System to preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation, which can potentially provide patients with end-stage heart failure with the life-saving treatment. Clinical Trial Registration: NCT03831048 (ClinicalTrials.gov.

AB - Orthotopic heart transplantation is the gold standard treatment for end-stage heart failure. However, the persistent shortage of available donor organs has resulted in an ever-increasing waitlist and longer waiting periods for transplantation. On the contrary, increasing the number of heart transplants by preserving extended criteria donors and donation after circulatory death hearts with the Organ Care System™ (OCS) Heart System has the potential to provide the gold standard, life-saving treatment to patients with end-stage heart failure. The objective of the Donation After Circulatory Death Heart Trial is to evaluate the effectiveness of the OCS Heart System to preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation, which can potentially provide patients with end-stage heart failure with the life-saving treatment. Clinical Trial Registration: NCT03831048 (ClinicalTrials.gov.

KW - donation after circulatory death

KW - ex situ heart perfusion

KW - heart transplantation

UR - http://www.scopus.com/inward/record.url?scp=85098601321&partnerID=8YFLogxK

U2 - 10.2217/fca-2020-0070

DO - 10.2217/fca-2020-0070

M3 - Review article

C2 - 32628044

AN - SCOPUS:85098601321

SN - 1479-6678

VL - 17

SP - 11

EP - 17

JO - Future Cardiology

JF - Future Cardiology

IS - 1

ER -

Donors after circulatory death heart trial

Abstract

Keywords

Access to Document

Fingerprint

Cite this